Does torcetrapib reduce the progression of atherosclerotic disease? Commentary

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 9, 2007, Pages 478-479

  Gotto, Antonio M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; APOLIPOPROTEIN A1; ATORVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEPTIDE DERIVATIVE; PLACEBO; TORCETRAPIB;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOGRAPHY; FOLLOW UP; HUMAN; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 34548274084     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0946     Document Type: Short Survey

References (6)

1. Cutri BA et al. (2006) High-density lipoproteins: An emerging target in the prevention of cardiovascular disease. Cell Res 16 799-808
2. Grundy SM et al. for the Coordinating Committee of the National Cholesterol Education Program (2004) Implications for recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel guidelines. J Am Coll Cardiol 44: 720-732
3. Robins SJ et al. for the VA-HIT Study Group (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT - a randomized controlled trial. JAMA 285: 1585-1591.
4. McKenney JM et al. (2006) Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 48: 1782-1790.
5. Tall AR et al. (2007) The failure of torcetrapib: Was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27: 257-260.
6. Rader DJ (2007) Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 4: 102-109